Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2020, Vol. 25 ›› Issue (11): 1283-1287.doi: 10.12092/j.issn.1009-2501.2020.11.009

Previous Articles     Next Articles

Side effects of lopinavir/ritonavir for COVID-19

,SHENG Haoyu, QUAN Bin, LIANG Manman, WU Qiongle, YANG Jianghua   

  1. Department of Infectious Diseases, Yijishan Hospital, Wannan Medical College, Wuhu 241001, Anhui, China
  • Received:2020-05-22 Revised:2020-09-20 Online:2020-11-26 Published:2020-12-17

Abstract: AIM: To study the regularity and characteristics of side effects of lopinavir/ritonavir for COVID-19.  METHODS: The type of side effects, general information, medical history and prognosis in 61 confirmed and suspected COVID-19 patients with lopinavir/ritonavir were analyzed. RESULTS: Among the 61 patients, 41(67.21%) had lopinavir/ritonavir related side effects, mainly manifested as gastrointestinal reactions (82.93%) and liver function damage (53.66%). Old age, long course of disease and chronic gastrointestinal disease are independent risk factors for side effects. CONCLUSION: Lopinavir/ritonavir has a high incidence of side effects and can be used in COVID-19 patients under the condition of close observation of the patient's symptoms and test results. Special population should improve pharmaceutical care to ensure the safety of drug use.

Key words: lopinavir/ritonavir, COVID-19, side effects

CLC Number: